New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma

H3K27M-mutant diffuse midline gliomas (DMGs) are rare childhood central nervous system tumors that carry a dismal prognosis. Thus, innovative treatment approaches are greatly needed to improve clinical outcomes for these patients. Here, we discuss current trends in research of H3K27M-mutant diffuse...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davis P. Argersinger, Sarah R. Rivas, Ashish H. Shah, Sadhana Jackson, John D. Heiss
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biopsy diffuse midline glioma H3K27M-mutant immunotherapy diffuse intrinsic pontine glioma (DIPG) radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b9777d6178d8452eb0ff36817324d0b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9777d6178d8452eb0ff36817324d0b9
record_format	dspace
spelling	oai:doaj.org-article:b9777d6178d8452eb0ff36817324d0b92021-11-11T15:26:58ZNew Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma10.3390/cancers132152802072-6694https://doaj.org/article/b9777d6178d8452eb0ff36817324d0b92021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5280https://doaj.org/toc/2072-6694H3K27M-mutant diffuse midline gliomas (DMGs) are rare childhood central nervous system tumors that carry a dismal prognosis. Thus, innovative treatment approaches are greatly needed to improve clinical outcomes for these patients. Here, we discuss current trends in research of H3K27M-mutant diffuse midline glioma. This review highlights new developments of molecular pathophysiology for these tumors, as they relate to epigenetics and therapeutic targeting. We focus our discussion on combinatorial therapies addressing the inherent complexity of treating H3K27M-mutant diffuse midline gliomas and incorporating recent advances in immunotherapy, molecular biology, genetics, radiation, and stereotaxic surgical diagnostics.Davis P. ArgersingerSarah R. RivasAshish H. ShahSadhana JacksonJohn D. HeissMDPI AGarticlebiopsydiffuse midline gliomaH3K27M-mutantimmunotherapydiffuse intrinsic pontine glioma (DIPG)radiotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5280, p 5280 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biopsy diffuse midline glioma H3K27M-mutant immunotherapy diffuse intrinsic pontine glioma (DIPG) radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	biopsy diffuse midline glioma H3K27M-mutant immunotherapy diffuse intrinsic pontine glioma (DIPG) radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Davis P. Argersinger Sarah R. Rivas Ashish H. Shah Sadhana Jackson John D. Heiss New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
description	H3K27M-mutant diffuse midline gliomas (DMGs) are rare childhood central nervous system tumors that carry a dismal prognosis. Thus, innovative treatment approaches are greatly needed to improve clinical outcomes for these patients. Here, we discuss current trends in research of H3K27M-mutant diffuse midline glioma. This review highlights new developments of molecular pathophysiology for these tumors, as they relate to epigenetics and therapeutic targeting. We focus our discussion on combinatorial therapies addressing the inherent complexity of treating H3K27M-mutant diffuse midline gliomas and incorporating recent advances in immunotherapy, molecular biology, genetics, radiation, and stereotaxic surgical diagnostics.
format	article
author	Davis P. Argersinger Sarah R. Rivas Ashish H. Shah Sadhana Jackson John D. Heiss
author_facet	Davis P. Argersinger Sarah R. Rivas Ashish H. Shah Sadhana Jackson John D. Heiss
author_sort	Davis P. Argersinger
title	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
title_short	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
title_full	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
title_fullStr	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
title_full_unstemmed	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
title_sort	new developments in the pathogenesis, therapeutic targeting, and treatment of h3k27m-mutant diffuse midline glioma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b9777d6178d8452eb0ff36817324d0b9
work_keys_str_mv	AT davispargersinger newdevelopmentsinthepathogenesistherapeutictargetingandtreatmentofh3k27mmutantdiffusemidlineglioma AT sarahrrivas newdevelopmentsinthepathogenesistherapeutictargetingandtreatmentofh3k27mmutantdiffusemidlineglioma AT ashishhshah newdevelopmentsinthepathogenesistherapeutictargetingandtreatmentofh3k27mmutantdiffusemidlineglioma AT sadhanajackson newdevelopmentsinthepathogenesistherapeutictargetingandtreatmentofh3k27mmutantdiffusemidlineglioma AT johndheiss newdevelopmentsinthepathogenesistherapeutictargetingandtreatmentofh3k27mmutantdiffusemidlineglioma
_version_	1718435330715025408

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma

Ejemplares similares